At the time of writing, Ocular Therapeutix Inc [OCUL] stock is trading at $6.02, down -4.44%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OCUL shares have lost -7.95% over the last week, with a monthly amount drifted -21.31%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 18, 2025, and set its price target to $17. On March 11, 2025, Needham initiated with a Buy rating and assigned a price target of $15 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating. TD Cowen upgraded its rating to a Buy and raised its price target to $11 on June 20, 2024. In a note dated February 09, 2024, BofA Securities initiated an Buy rating and provided a target price of $15 on this stock.
For the past year, the stock price of Ocular Therapeutix Inc fluctuated between $4.06 and $11.77. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $6.02 at the most recent close of the market. An investor can expect a potential return of 215.61% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
According to Ocular Therapeutix Inc [NASDAQ:OCUL], the company’s sales were 63.72M for trailing twelve months, which represents an 15.40% jump. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -2.7%, Pretax Profit Margin comes in at -3.04%, and Net Profit Margin reading is -3.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.53 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.72 points at the first support level, and at 5.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.53, and for the 2nd resistance point, it is at 7.04.
Ratios To Look Out For
It is important to note that Ocular Therapeutix Inc [NASDAQ:OCUL] has a current ratio of 10.66. As well, the Quick Ratio is 10.59, while the Cash Ratio is 9.48. Considering the valuation of this stock, the price to sales ratio is 15.02, the price to book ratio is 3.01.
Transactions by insiders
Recent insider trading involved Dugel Pravin,, that happened on Feb 24 ’25 when 21475.0 shares were sold. Chief Scientific Officer, Heier Jeffrey S. completed a deal on Feb 24 ’25 to sell 3061.0 shares. Meanwhile, Chief Development Officer Kaiser Peter sold 3009.0 shares on Feb 24 ’25.
